Lisata Therapeutics Inc (LSTA)

[etpa]

Results were actually excellent per
Steven Giardino comment on his recent article on Celldex at Seeeking Alpha. Excerpt:

"...I thought the [NBS] data was excellent, but everyone is caught up with perfusion. It means nothing to FDA, however. Too inconsistent and unreliable. In 6 months another data update will likely show an even greater improvement as the curves between tx and placebo separate further, and in the meantime a partner will potentially step forward (perhaps BAX). The Ph III will be a go, and the stock should see $7s plus again.

"I'm absolutely a buyer at these levels."